<DOC>
	<DOCNO>NCT02257905</DOCNO>
	<brief_summary>Light-chain ( AL- ) amyloidosis rare monoclonal plasma cell disorder poor prognosis . Rarity disease preclude performance randomize control trial compare various possible treatment modality . In general , treatment AL amyloidosis adapt myeloma ( MM ) therapy . There large experience allo SCT MM . Based small series patient case report allogeneic transplant emerge potentially effective . However , formal proof concept use allogeneic hematopoietic transplantation treatment AL Amyloidosis lacking . Therefore , give limitation conventionally collect registry data ( dubious follow-up information extreme heterogeneity ) , develop : `` EBMT non-interventional prospective study allogeneic transplantation AL Amyloidosis '' mean transplant center already perform allogeneic transplant AL Amyloidosis encourage register patient AL Amyloidosis timely EBMT , follow mandatory submission EBMT MedB follow-up form . The diagnosis AL Amyloidosis would base uniform criterion . All EBMT centre perform allogeneic transplant Amyloidosis invite participate study centre ask report AL Amyloidosis case refer transplantation use simple registration form submit Amyloidosis MED B form transplant patient follow-up form necessary . In conclusion , possible largely improve usual quality registry-based data generate scientifically sound knowledge HSCT orphan disease AL Amyloidosis .</brief_summary>
	<brief_title>Allo SCT Amyloidosis Non-interventional Study</brief_title>
	<detailed_description>Short description study : We plan select centre within EBMT past perform allogeneic transplant amyloidosis ask participate complete centre registration form . When patient want include study , centre notify CLWP data office plan allogeneic transplant day transplant take place . For , centre use patient registration form . Once patient include , MED B regular follow-up mandatory . Data entry MED B form follow perform way usual centre ( either centre , national registry Paris data office ) . The CLWP data office keep track data submit . Research design : This study design non-interventional prospective study . Study Population : Male female subject , 18 year 60 year , AL amyloidosis receive allogeneic transplantation . Data collected/analysed : The primary endpoint study efficacy ( best hematological remission organ response ) allogeneic SCT patient AL amyloidosis . The secondary endpoint acute chronic GvHD , TRM event-free overall survival . Purpose non-interventional prospective study request : The main purpose non-interventional prospective study evaluation effectiveness allogeneic transplant AL Amyloidosis . It plan result present scientific symposium suffice least one publication ( original article ) .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>AL Amyloidosis , allogeneic HSCT November 2009 , 1860 year time transplant . diagnose AL Amyloidosis , auto transplant , transplant November 2009 , young 18 old 60 time transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>AL Amyloidosis</keyword>
	<keyword>Amyloidosis</keyword>
	<keyword>allogeneic</keyword>
	<keyword>HSCT</keyword>
</DOC>